(Bio)pharma continuous manufacturing market to reach $2.3 billion by 2027

A new market research report indicates that the global continuous manufacturing market for pharmaceuticals and biopharmaceuticals is predicted to reach $2.3 billion by 2027 and is expected to expand at a compound annual growth rate (CAGR) of 13.85 percent from 2021 to 2027 (the forecast period).

Some of the global drivers include drug shortage, more stringent requirements for consistent quality, the need for reduced processing costs, and the demand for higher and improved productivity. Moreover, the growing demand for biosimilars and an ever-increasing pressure for reducing drug development costs are also driving revenue.

The report states that North America led the global market in 2020. This is attributed to the presence of key technology developers as well as high R&D expenditure in drug development by the end-users in the US Key players are implementing various strategies to strengthen their product offerings and offer diverse technologically advanced products to accelerate therapeutics development.

In terms of therapeutics type, the pharmaceutical/small molecules segment dominated the market in 2020 owing to high technology penetration in this segment. According to the report, the biopharmaceutical/large molecules segment is anticipated to witness lucrative growth owing to increasing investment in facility expansion to integrate continuous manufacturing systems. Furthermore, by formulation, solid formulation dominated the market in 2020 owing to the maximum adoption of continuous manufacturing methodologies in solid drug production.

Key players in the global continuous manufacturing market for pharmaceuticals and biopharmaceuticals include Thermo Fisher Scientific, Merck KGaA, Electrolab Biotech, Lonza Group AG, GlaxoSmithKline (GSK), Amgen, GEA Group, Boehringer Ingelheim International and Sartorius Stedim Biotech.